Hypercholesterolemia induced by a PCSK9 gain-of-function mutation augments angiotensin II-induced abdominal aortic aneurysms in C57BL/6 mice-brief report

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 9, 2016, Pages 1753-1757

  Lu, Hong ^a   Howatt, Deborah A ^a   Balakrishnan, Anju ^a   Graham, Mark J ^b   Mullick, Adam E ^b   Daugherty, Alan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Aortic aneurysms; Atherosclerosis; Hypercholesterolemia; Low density lipoprotein; Mouse; Pcsk9 protein

Indexed keywords

ANGIOTENSIN II; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PARVOVIRUS VECTOR; SATURATED FATTY ACID; BIOLOGICAL MARKER; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; PARVOVIRUS INFECTION; PCSK9 GENE; PRIORITY JOURNAL; 129 MOUSE; ABDOMINAL AORTIC ANEURYSM; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DBA MOUSE; DEFICIENCY; DEPENDOPARVOVIRUS; DISEASE MODEL; ENZYMOLOGY; GENE TRANSFER; GENE VECTOR; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUTATION; SPECIES DIFFERENCE; TIME FACTOR;

ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; BIOMARKERS; CHOLESTEROL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VECTORS; HYPERCHOLESTEROLEMIA; MALE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84983780951     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307613     Document Type: Article

References (22)

1. Liu J, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Sorci-Thomas M, Cassis LA, Daugherty A, Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2015 35 1826 1834. doi: 10.1161/ATVBAHA.115.305482
2. Liu J, Daugherty A, Lu H, Angiotensin II and Abdominal Aortic Aneurysms: An update. Curr Pharm Des 2015 21 4035 4048
3. Daugherty A, Cassis L, Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/-mice. Ann N Y Acad Sci 1999 892 108 118
4. Daugherty A, Manning MW, Cassis LA, Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000 105 1605 1612. doi: 10.1172/JCI7818
5. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A, Urokinase-Type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011 31 2845 2852. doi: 10.1161/ATVBAHA.111.234997
6. King VL, Trivedi DB, Gitlin JM, Loftin CD, Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006 26 1137 1143. doi: 10.1161/01.ATV.0000216119.79008.ac
7. Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M, Thinnes T, Loskutoff DJ, Carmeliet P, Dole WP, Wang YX, Urokinase-Type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res 2003 92 510 517. doi: 10.1161/01.RES.0000061571.49375.E1
8. Daugherty A, Tabas I, Rader DJ, Accelerating the pace of atherosclerosis research. Arterioscler Thromb Vasc Biol 2015 35 11 12. doi: 10.1161/ATVBAHA.114.304833
9. Lu H, Daugherty A, Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 2015 26 152 153. doi: 10.1097/MOL.0000000000000166
10. Horton JD, Cohen JC, Hobbs HH, PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009 50 S172 S177. doi: 10.1194/jlr.R800091-JLR200
11. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161
12. Bjørklund MM, Hollensen AK, Hagensen MK, Dagnaes-Hansen F, Christoffersen C, Mikkelsen JG, Bentzon JF, Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res 2014 114 1684 1689. doi: 10.1161/CIRCRESAHA.114.302937
13. Roche-Molina M, Sanz-Rosa D, Cruz FM, García-Prieto J, López S, Abia R, Muriana FJ, Fuster V, Ibáñez B, Bernal JA, Induction of sustained hypercholesterolemia by single adeno-Associated virus-mediated gene transfer of mutant hPCSK9. Arterioscler Thromb Vasc Biol 2015 35 50 59. doi: 10.1161/ATVBAHA.114.303617
14. Wu C, Xu Y, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Vander Kooi CW, Cassis LA, Wang JA, Daugherty A, Cys18-Cys137 disulfide bond in mouse angiotensinogen does not affect AngII-dependent functions in vivo. Hypertension 2015 65 800 805. doi: 10.1161/HYPERTENSIONAHA.115.05166
15. Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A, Angiotensinogen exerts effects independent of angiotensin II. Arterioscler Thromb Vasc Biol 2016 36 256 265. doi: 10.1161/ATVBAHA.115.306740
16. Maxwell KN, Breslow JL, Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol 2005 16 167 172
17. Attie AD, Seidah NG, Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab 2005 1 290 292. doi: 10.1016/j.cmet.2005.04.006
18. Deeg MA, Meijer CA, Chan LS, Shen L, Lindeman JH, Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate. Curr Med Res Opin 2016 32 509 517. doi: 10.1185/03007995.2015.1128406
19. Forsdahl SH, Singh K, Solberg S, Jacobsen BK, Risk factors for abdominal aortic aneurysms: A 7-year prospective study: The Tromsø Study, 1994-2001. Circulation 2009 119 2202 2208. doi: 10.1161/CIRCULATIONAHA.108.817619
20. Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG, Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 2013 8 e64145. doi: 10.1371/journal.pone.0064145
21. Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S, Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol 2016 238 52 62. doi: 10.1002/path.4630
22. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S, Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 2014 130 431 441. doi: 10.1161/CIRCULATIONAHA.113.006720. This article was sent to Karin Bornfeldt, Consulting Editor, for review by expert referees, editorial decision, and final disposition